ADC Therapeutics News

Express News | HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $9 Price Target

Moomoo 24/7Apr 15 07:51 ET

Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress

TipRanksApr 15 06:16 ET

Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)

TipRanksApr 11 11:30 ET

ADC Therapeutics Showcases Cancer Treatment Innovations

TipRanksApr 9 16:23 ET

Express News | Guggenheim Reiterates Buy on ADC Therapeutics

Moomoo 24/7Apr 5 09:55 ET

Sector Update: Health Care Stocks Slump Late Afternoon

Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each dropping 1.3%. The iShares Biotechnology ETF (IBB) shed 1.4%. In

MT NewswiresApr 4 16:03 ET

Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), TFF Pharmaceuticals (TFFP)

TipRanksApr 4 13:20 ET

ADC Therapeutics Gains After Data for Lymphoma Therapy

Seeking AlphaApr 4 13:11 ET

Express News | ADC Therapeutics Shares Are Trading Higher. The Company Announced the Completion of Dose Escalation in LOTIS-7, a Phase 1b Open-label Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Heavily Pre-treated Patients With R

Moomoo 24/7Apr 4 10:50 ET

Express News | ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Moomoo 24/7Apr 4 07:05 ET

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the "Company") (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,

GlobeNewswireApr 1 16:05 ET

Chiome Bioscience Cancels License Agreements With ADC Therapeutics

Chiome Bioscience (TYO:4583) has cancelled license agreements with ADC Therapeutics related to the development and commercialization of the anti-DLK-1 antibody, LIV-1205, according to its filing last

MT NewswiresMar 31 23:06 ET

Express News | ADC Therapeutics Shares Are Trading Higher After Guggenheim Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $11

Moomoo 24/7Mar 28 11:32 ET

ADC Therapeutics Initiated at Buy by Guggenheim

ADC Therapeutics Initiated at Buy by Guggenheim

Dow JonesMar 28 06:56 ET

Express News | Guggenheim Initiates Coverage On ADC Therapeutics With Buy Rating, Announces Price Target of $11

Moomoo 24/7Mar 28 06:45 ET

ADC Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 158.82% Guggenheim → $11 Initiates Coverage On → Buy 03/14/2024 88.24% RBC Capital → $8 Reitera

BenzingaMar 28 06:44 ET

US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results

Yahoo FinanceMar 16 08:32 ET

Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)

TipRanksMar 15 21:50 ET

ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 15 12:30 ET

Earnings Call: ADC Therapeutics Optimistic Amid Q4 and Full-year 2023 Results

InvestingMar 14 18:18 ET